Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has been granted patent protection in China for its T cell receptor (TCR) technology targeting NY-ESO-1 and LAGE 1a. This development pertains to the company’s lead pipeline candidate, MDG1015, which is a first-in-class, third-generation TCR-T therapy. MDG1015 targets NY-ESO-1/LAGE1a and is armed and enhanced by the co-stimulatory switch protein PD1-41BB. The patent protection in China complements similar awards that Medigene has received in the US, EU, Japan, South Korea, and Australia.
As detailed in the company’s press release, the patent effectively covers a core component of MDG1015. Medigene is advancing preparations for the molecule’s first Investigational New Drug (IND) filing in the US, scheduled for the third quarter of 2024. The initial clinical targets for MDG1015 include gastric cancer, ovarian cancer, myxoid/round cell liposarcoma, and synovial sarcoma. Preclinical data for this molecule has been presented at prestigious conferences such as the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO) during 2023.- Flcube.com
